UPXI

Company Overview — What Does UPEXI, INC. Do?

Upexi, Inc. engages in the development, manufacture, and distribution of consumer products. It offers nail grinder and healthy all-natural pet supplements under the LuckyTail brand; energy solutions under the PRAX brand; functional mushrooms under the Cure Mushrooms brand; cannabinoid under the Moonwlkr brand; and gummies and other products under the Gumi Labs brand name. The company sells its products through direct-to-consumer network, wholesale partnerships, and third-party platform. It also focuses on cryptocurrency industry and management of cash assets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. Upexi, Inc. was incorporated in 2018 and is headquartered in Tampa, Florida. UPEXI, INC. (UPXI) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Allan Marshall and employs approximately 59 people. With a market capitalization of $68M, UPXI is one of the notable companies in the Healthcare sector.

UPEXI, INC. (UPXI) Stock Rating — Avoid (April 2026)

As of April 2026, UPEXI, INC. receives a Avoid rating with a composite score of 19.6/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.UPXI ranks #4,291 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, UPEXI, INC. ranks #780 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

UPXI Stock Price and 52-Week Range

UPEXI, INC. (UPXI) currently trades at $1.10. The stock gained $0.06 (5.8%) in the most recent trading session. The 52-week high for UPXI is $22.57, which means the stock is currently trading -95.1% from its annual peak. The 52-week low is $0.54, putting the stock 103.7% above its annual trough. Recent trading volume was 2.3M shares, reflecting moderate market activity.

Is UPXI Overvalued or Undervalued? — Valuation Analysis

UPEXI, INC. (UPXI) carries a value factor score of 8/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.33x, versus the sector average of 2.75x. The price-to-sales ratio is 2.65x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, UPXI trades at 1.21x EV/EBITDA, versus 6.34x for the sector.

At current multiples, UPEXI, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

UPEXI, INC. Profitability — ROE, Margins, and Quality Score

UPEXI, INC. (UPXI) earns a quality factor score of 14/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -240.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -43.3% versus the sector average of -33.1%.

On a margin basis, UPEXI, INC. reports gross margins of 74.1%, compared to 71.5% for the sector. The operating margin is -392.4% (sector: -66.1%). Net profit margin stands at -413.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 84.8% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

UPXI Debt, Balance Sheet, and Financial Health

UPEXI, INC. has a debt-to-equity ratio of 457.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 2.20x, indicating strong short-term liquidity.

UPXI has a beta of 0.16, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for UPEXI, INC. is 28/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

UPEXI, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, UPEXI, INC. reported revenue of $24M and earnings per share (EPS) of $-2.94. Net income for the quarter was $-117M. Gross margin was 74.1%. Operating income came in at $-111M.

In Q2 2026, UPEXI, INC. reported revenue of $8M and earnings per share (EPS) of $-2.94. Net income for the quarter was $-179M. Gross margin was 83.4%. Revenue grew 101.0% year-over-year compared to Q2 2025. Operating income came in at $-175M.

In Q1 2026, UPEXI, INC. reported revenue of $9M and earnings per share (EPS) of $1.21. Net income for the quarter was $67M. Gross margin was 89.6%. Revenue grew 112.1% year-over-year compared to Q1 2025. Operating income came in at $69M.

In FY 2025, UPEXI, INC. reported revenue of $16M and earnings per share (EPS) of $-1.73. Net income for the quarter was $-14M. Gross margin was 68.7%. Revenue grew -39.2% year-over-year compared to FY 2024. Operating income came in at $-12M.

Over the past 8 quarters, UPEXI, INC. has experienced revenue contraction from $26M to $24M. Investors analyzing UPXI stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

UPXI Dividend Yield and Income Analysis

UPEXI, INC. (UPXI) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

UPXI Momentum and Technical Analysis Profile

UPEXI, INC. (UPXI) has a momentum factor score of 10/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 68/100 reflects moderate short selling activity.

UPXI vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, UPEXI, INC. (UPXI) ranks #780 out of 838 stocks based on the Blank Capital composite score. This places UPXI in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing UPXI against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full UPXI vs S&P 500 (SPY) comparison to assess how UPEXI, INC. stacks up against the broader market across all factor dimensions.

UPXI Next Earnings Date

No upcoming earnings date has been announced for UPEXI, INC. (UPXI) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy UPXI? — Investment Thesis Summary

The quantitative profile for UPEXI, INC. suggests caution. The quality score of 14/100 flags below-average profitability. The value score of 8/100 indicates premium valuation. Momentum is weak at 10/100, a headwind for near-term performance. High volatility (stability score 28/100) increases portfolio risk.

In summary, UPEXI, INC. (UPXI) earns a Avoid rating with a composite score of 19.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on UPXI stock.

Related Resources for UPXI Investors

Explore more research and tools: UPXI vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare UPXI head-to-head with peers: UPXI vs AZN, UPXI vs SLGL, UPXI vs VMD.